SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: erippetoe who wrote (62864)10/19/2024 8:05:15 PM
From: stockdoc772 Recommendations

Recommended By
erickerickson
rodneyh07

  Read Replies (1) of 63324
 
To pull a drug in P3 that has almost finished the trial when there is no safety issue would be absurd. The questions about the validity of some of the basic science it was based on are real and should not be dismissed, but to shut down the P3 makes no sense. We have a terrible disease with no treatment, and there is a non zero chance the drug works, so why not find out? The fact that 90% of the study population has chosen to continue on drug after completing the trial certainly argues that we find out the answer. Still, I am at this point resigned to the study being a failure, and will be shocked by a positive P3. Only FOMO keeps me from selling my (small, relatively speaking) stake.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News